After setting the industry ablaze last month, a bipartisan bill aimed at restricting US biotech companies from striking deals with Chinese counterparts is in limbo. The Biotech Investment National …
Source: Endpoints News
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.